标题
The Discovery and Development of Liraglutide and Semaglutide
作者
关键词
-
出版物
Frontiers in Endocrinology
Volume 10, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2019-04-12
DOI
10.3389/fendo.2019.00155
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus
- (2018) Bruno Vergès et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- α-Helix or β-Turn? An Investigation into N-Terminally Constrained Analogues of Glucagon-like Peptide 1 (GLP-1) and Exendin-4
- (2018) Alberto Oddo et al. BIOCHEMISTRY
- Bone markers and cardiovascular risk in type 2 diabetes patients
- (2018) Sabine R. Zwakenberg et al. Cardiovascular Diabetology
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
- (2018) Daniel J. Drucker Cell Metabolism
- Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease
- (2018) Subodh Verma et al. CIRCULATION
- Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor–Expressing Glutamatergic Neurons
- (2018) Jessica M. Adams et al. DIABETES
- Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial
- (2018) Michael A Nauck et al. Diabetes & Vascular Disease Research
- A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin
- (2018) Ildiko Lingvay et al. DIABETES CARE
- Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience
- (2018) Bernard Zinman et al. DIABETES CARE
- Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
- (2018) Bo Ahrén et al. DIABETES OBESITY & METABOLISM
- Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment
- (2018) Lene Jensen et al. DIABETES OBESITY & METABOLISM
- Incretin hormones: Their role in health and disease
- (2018) Michael A. Nauck et al. DIABETES OBESITY & METABOLISM
- Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
- (2018) Seung Pil Yun et al. NATURE MEDICINE
- Fire prevention in the Parkinson’s disease brain
- (2018) Lena Brundin et al. NATURE MEDICINE
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
- (2018) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications
- (2018) Daniel J. Drucker DIABETES
- The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial
- (2018) Ketan Dhatariya et al. DIABETES CARE
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- Structure of the glucagon receptor in complex with a glucagon analogue
- (2018) Haonan Zhang et al. NATURE
- Integrated Brain Atlas for Unbiased Mapping of Nervous System Effects Following Liraglutide Treatment
- (2018) Casper Bo Gravesen Salinas et al. Scientific Reports
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist
- (2018) Stephen T. Buckley et al. Science Translational Medicine
- Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species
- (2017) Lene Jensen et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Strategies and industrial perspectives to improve oral absorption of biological macromolecules
- (2017) Chang Liu et al. Expert Opinion on Drug Delivery
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
- (2017) Melanie Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Impact of the Glucagon Assay When Assessing the Effect of Chronic Liraglutide Therapy on Glucagon Secretion
- (2017) Caroline K Kramer et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Extracellular matrix proteomics identifies molecular signature of symptomatic carotid plaques
- (2017) Sarah R. Langley et al. JOURNAL OF CLINICAL INVESTIGATION
- Activation of murine pre-proglucagon–producing neurons reduces food intake and body weight
- (2017) Ronald P. Gaykema et al. JOURNAL OF CLINICAL INVESTIGATION
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
- (2017) Dilan Athauda et al. LANCET
- Structure of the full-length glucagon class B G-protein-coupled receptor
- (2017) Haonan Zhang et al. NATURE
- Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein
- (2017) Yan Zhang et al. NATURE
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis
- (2017) Carel le Roux et al. Obesity Facts
- Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
- (2017) Bo Ahrén et al. Lancet Diabetes & Endocrinology
- Semaglutide, lipid-lowering drugs, and NAFLD
- (2017) Niki Katsiki et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
- (2017) Christopher Sorli et al. Lancet Diabetes & Endocrinology
- The dynamic plasticity of insulin production in β-cells
- (2017) Brandon B. Boland et al. Molecular Metabolism
- The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice
- (2017) Laurie L. Baggio et al. Molecular Metabolism
- Blood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment
- (2017) Michael Gejl et al. Scientific Reports
- Human Validation of Genes Associated With a Murine Atherosclerotic PhenotypeHighlights
- (2016) Gerard Pasterkamp et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy
- (2016) Henrik H. Hansen et al. BRAIN RESEARCH
- Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study
- (2016) Manfredi Rizzo et al. Cardiovascular Diabetology
- Never Waste a Good Crisis: Confronting Reproducibility in Translational Research
- (2016) Daniel J. Drucker Cell Metabolism
- Parabrachial CGRP Neurons Control Meal Termination
- (2016) Carlos A. Campos et al. Cell Metabolism
- Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease
- (2016) Børge G. Nordestgaard CIRCULATION RESEARCH
- The Hypothalamic Glucagon-Like Peptide 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice
- (2016) Melissa A. Burmeister et al. DIABETES
- Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
- (2016) Michael Nauck et al. DIABETES CARE
- Exposure-response analyses of liraglutide 3.0 mg for weight management
- (2016) J. P. H. Wilding et al. DIABETES OBESITY & METABOLISM
- Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015)
- (2016) Eun Ji Park et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- GLP-1 Induces Barrier Protective Expression in Brunnerʼs Glands and Regulates Colonic Inflammation
- (2016) Claus H. Bang-Berthelsen et al. INFLAMMATORY BOWEL DISEASES
- Structural Determinants of Binding the Seven-transmembrane Domain of the Glucagon-like Peptide-1 Receptor (GLP-1R)
- (2016) Dehua Yang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel Biomarkers to Improve the Prediction of Cardiovascular Event Risk in Type 2 Diabetes Mellitus
- (2016) Joep van der Leeuw et al. Journal of the American Heart Association
- Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
- (2016) Nicolai J. Wewer Albrechtsen et al. Journal of Diabetes Research
- GLP-1R Agonists Promote Normal and Neoplastic Intestinal Growth through Mechanisms Requiring Fgf7
- (2015) Jacqueline A. Koehler et al. Cell Metabolism
- GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R
- (2015) Bernardo Yusta et al. DIABETES
- Deciphering Metabolic Messages From the Gut Drives Therapeutic Innovation: The 2014 Banting Lecture
- (2015) Daniel J. Drucker DIABETES
- Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
- (2015) Juris J. Meier et al. DIABETES CARE
- Expression and Distribution of Glucagon-Like Peptide-1 Receptor mRNA, Protein and Binding in the Male Nonhuman Primate (Macaca mulatta) Brain
- (2015) Kristy M. Heppner et al. ENDOCRINOLOGY
- Intestinal GLP-1 and satiation: from man to rodents and back
- (2015) R E Steinert et al. INTERNATIONAL JOURNAL OF OBESITY
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial
- (2015) Caroline K. Kramer et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
- (2015) Jesper Lau et al. JOURNAL OF MEDICINAL CHEMISTRY
- Islet α cells and glucagon—critical regulators of energy homeostasis
- (2015) Jonathan E. Campbell et al. Nature Reviews Endocrinology
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice
- (2015) Gunnar Sørensen et al. PHYSIOLOGY & BEHAVIOR
- A Method for Combining RNAscope In Situ Hybridization with Immunohistochemistry in Thick Free-Floating Brain Sections and Primary Neuronal Cultures
- (2015) Tessa M. Grabinski et al. PLoS One
- Structural similarities and differences between the human and the mouse pancreas
- (2015) Jurij Dolenšek et al. Islets
- Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics
- (2015) Kine Marita Knudsen Sand et al. Frontiers in Immunology
- Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain
- (2015) Simon C. Cork et al. Molecular Metabolism
- Structure of Class B GPCRs: new horizons for drug discovery
- (2014) Andrea Bortolato et al. BRITISH JOURNAL OF PHARMACOLOGY
- Hypothalamic Tanycytes Are an ERK-Gated Conduit for Leptin into the Brain
- (2014) Eglantine Balland et al. Cell Metabolism
- GLP-1 Provoked Severe Hypoglycemia in an Individual With Type 2 Diabetes and a Benign Insulinoma
- (2014) Ronald J. Ruby et al. DIABETES CARE
- Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
- (2014) Carol Wysham et al. DIABETES CARE
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
- (2014) Charles Pyke et al. ENDOCRINOLOGY
- A head-to-head multi-parametric high content analysis of a series of medium chain fatty acid intestinal permeation enhancers in Caco-2 cells
- (2014) David J. Brayden et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
- (2014) Anna Secher et al. JOURNAL OF CLINICAL INVESTIGATION
- Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight
- (2014) Laurie L. Baggio et al. JOURNAL OF CLINICAL INVESTIGATION
- Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect
- (2014) Stephanie Sisley et al. JOURNAL OF CLINICAL INVESTIGATION
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
- (2014) Kathleen M Dungan et al. LANCET
- Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas
- (2014) Beatrice Waser et al. MODERN PATHOLOGY
- A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis
- (2014) Yuko Tashiro et al. PEPTIDES
- Dopamine signaling in the amygdala, increased by food ingestion and GLP-1, regulates feeding behavior
- (2014) Rozita H. Anderberg et al. PHYSIOLOGY & BEHAVIOR
- Effects of GLP-1 in the Kidney
- (2014) Jeppe Skov REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
- (2014) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty
- (2013) Astrid Plamboeck et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Progress in detecting cell-surface protein receptors: the erythropoietin receptor example
- (2013) Steve Elliott et al. ANNALS OF HEMATOLOGY
- Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat
- (2013) Weike Bao et al. Cardiovascular Diabetology
- The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE−/− mouse model
- (2013) Tracey Gaspari et al. Diabetes & Vascular Disease Research
- Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial
- (2013) K. Hermansen et al. DIABETES OBESITY & METABOLISM
- Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus
- (2013) Andrew E. Hogan et al. DIABETOLOGIA
- Glucagon-Like Peptide-1 (GLP-1) Reduces Mortality and Improves Lung Function in a Model of Experimental Obstructive Lung Disease in Female Mice
- (2013) Niels-Erik Viby et al. ENDOCRINOLOGY
- Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults
- (2013) M E J Lean et al. INTERNATIONAL JOURNAL OF OBESITY
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
- (2013) J van Can et al. INTERNATIONAL JOURNAL OF OBESITY
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2013) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- Tanycyte-like cells form a blood-cerebrospinal fluid barrier in the circumventricular organs of the mouse brain
- (2013) Fanny Langlet et al. JOURNAL OF COMPARATIVE NEUROLOGY
- Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
- (2013) L van Bloemendaal et al. JOURNAL OF ENDOCRINOLOGY
- Drugs derived from phage display
- (2013) Andrew E Nixon et al. mAbs
- Common variants associated with plasma triglycerides and risk for coronary artery disease
- (2013) Ron Do et al. NATURE GENETICS
- GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure
- (2013) Minsuk Kim et al. NATURE MEDICINE
- Effects of lixisenatide once daily on gastric emptying in type 2 diabetes — Relationship to postprandial glycemia
- (2013) Martin Lorenz et al. REGULATORY PEPTIDES
- Impact of Diabetes on Cardiovascular Disease: An Update
- (2013) Alessandra Saldanha de Mattos Matheus et al. International Journal of Hypertension
- Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice
- (2012) Lital Rachmany et al. AGE
- Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans
- (2012) Changting Xiao et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1–31)NH2] in postmenopausal women with osteoporosis
- (2012) K. Henriksen et al. BONE
- The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial
- (2012) J. Rosenstock et al. DIABETES CARE
- Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight
- (2012) J. Jelsing et al. DIABETES OBESITY & METABOLISM
- Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function
- (2012) T. Forst et al. DIABETIC MEDICINE
- GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic MaleApoE−/−Mice
- (2012) Naim Panjwani et al. ENDOCRINOLOGY
- The Glucagon-Like Peptide-1 Receptor—or Not?
- (2012) Charles Pyke et al. ENDOCRINOLOGY
- Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies
- (2012) LANCET
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
- (2012) John B Buse et al. LANCET
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
- (2012) Ib Jonassen et al. PHARMACEUTICAL RESEARCH
- Exendin-4 decreases amphetamine-induced locomotor activity
- (2012) Kevin Erreger et al. PHYSIOLOGY & BEHAVIOR
- Functional importance of GLP-1 receptor species and expression levels in cell lines
- (2012) Lotte Bjerre Knudsen et al. REGULATORY PEPTIDES
- Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor
- (2012) Jan Terje Andersen et al. Nature Communications
- The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen
- (2011) Christoph Kapitza et al. ADVANCES IN THERAPY
- Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
- (2011) M. A. Nauck et al. DIABETES
- Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes
- (2011) Mary Beth DeYoung et al. Diabetes Technology & Therapeutics
- 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma
- (2011) Dale O. Kiesewetter et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide
- (2011) Laszlo Hegedüs et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Treatment With Liraglutide-a Once-Daily GLP-1 Analog-Does Not Reduce the Bioavailability of Ethinyl Estradiol/Levonorgestrel Taken as an Oral Combination Contraceptive Drug
- (2011) Lisbeth V. Jacobsen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Impact of albumin on drug delivery — New applications on the horizon
- (2011) Bakheet Elsadek et al. JOURNAL OF CONTROLLED RELEASE
- Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
- (2010) Anne Flint et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Unique Arrangement of - and -Cells in Human Islets of Langerhans
- (2010) D. Bosco et al. DIABETES
- Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetes
- (2010) J. Z. Dong et al. DIABETES OBESITY & METABOLISM
- Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase
- (2010) M. Malm-Erjefalt et al. DRUG METABOLISM AND DISPOSITION
- Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
- (2010) Lotte Bjerre Knudsen et al. ENDOCRINOLOGY
- Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes
- (2010) Erin L St Onge et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Lessons Learned From the Development of Oral Calcitonin: The First Tablet Formulation of a Protein in Phase III Clinical Trials
- (2010) M. A. Karsdal et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
- (2010) Richard E Pratley et al. LANCET
- Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
- (2010) Ulrich Werner et al. REGULATORY PEPTIDES
- Lack of cardioprotection from subcutaneously and preischemic administered Liraglutide in a closed chest porcine ischemia reperfusion model
- (2009) Jens Kristensen et al. BMC Cardiovascular Disorders
- Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota
- (2009) Patrice D Cani et al. CURRENT OPINION IN PHARMACOLOGY
- Age-Dependent Decline in -Cell Proliferation Restricts the Capacity of -Cell Regeneration in Mice
- (2009) S.-I. Tschen et al. DIABETES
- GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
- (2009) M. H. Noyan-Ashraf et al. DIABETES
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
- (2009) B. Zinman et al. DIABETES CARE
- Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects
- (2009) M. A. Bush et al. DIABETES OBESITY & METABOLISM
- The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
- (2009) J. Hsieh et al. DIABETOLOGIA
- Lessons from the Crystallographic Analysis of Small Molecule Binding to Human Serum Albumin
- (2009) Stephen Curry Drug Metabolism and Pharmacokinetics
- Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy
- (2009) Morten A. Karsdal et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules
- (2009) Hongbin Liu et al. JOURNAL OF ENDOCRINOLOGY
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Lack of specificity of antibodies directed against human beta-adrenergic receptors
- (2009) Nazha Hamdani et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors
- (2009) Wisuit Pradidarcheep et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
- (2009) Y. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular evolution of mammalian incretin hormone genes
- (2009) David M. Irwin REGULATORY PEPTIDES
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
- (2008) Kiwon Ban et al. CIRCULATION
- Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes
- (2008) J.-P. Courrèges et al. DIABETIC MEDICINE
- Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus
- (2008) T. Vilsbøll et al. DIABETIC MEDICINE
- Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain
- (2008) Steffen Runge et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
- (2008) Felix Kratz JOURNAL OF CONTROLLED RELEASE
- Suitability of muscarinic acetylcholine receptor antibodies for immunohistochemistry evaluated on tissue sections of receptor gene-deficient mice
- (2008) Gitte Jositsch et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Should we be cautious on the use of commercially available antibodies to dopamine receptors?
- (2008) Serena Bodei et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Engineering of a femtomolar affinity binding protein to human serum albumin
- (2008) A. Jonsson et al. PROTEIN ENGINEERING DESIGN & SELECTION
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started